Celebrity Inventors
Mark Twain (Samuel L. Clemens) received Patent No. 121,992 for "An Improvement in Adjustable and Detachable Straps for Garments." He later received two more patents: one for a self-pasting scrapbook and one for a game to help players remember important historical dates.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8025865 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic su... | 09/27/2011 |
| 7993852 | MN/CA IX and cancer prognosis Herein disclosed are methods that are prognostic for neoplastic/preneoplastic disease in a subject vertebrate, wherein said disease is associated with a tissue that normally expresses MN, but which MN expression is lost or diminished upon carcinogenesis. Exemplary o... | 08/09/2011 |
| 7910691 | MN gene and protein Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular co... | 03/22/2011 |
| 7846673 | Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX'S coexpression with HER-2/neu/c-erbB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) found in body fluids, such as, urine and serum. Soluble CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a ... | 12/07/2010 |
| 7855185 | MN gene and protein Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular co... | 12/21/2010 |
| 7838240 | MN/CA IX/CA9 and renal cancer prognosis Herein disclosed are methods that are prognostic for renal cell carcinoma, particularly renal clear cell carcinoma, afflicting a vertebrate. An exemplary prognostic method comprises detecting the presence of, and quantitating the level and/or extent of a MN/CA9 gene... | 11/23/2010 |
| 7833739 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic su... | 11/16/2010 |
| 7833738 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic su... | 11/16/2010 |
| 7833737 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic su... | 11/16/2010 |
| 7833734 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic su... | 11/16/2010 |
| 7833728 | Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX's coexpression with HER-2/neu/c-erbB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) in body fluids, such as, urine and serum. Said s-CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a proteog... | 11/16/2010 |
| 7833514 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic su... | 11/16/2010 |
| 7829065 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably membrane-impermeant compounds, which inhibit the enzymati... | 11/09/2010 |
| 7820159 | MN/CA IX and EGFR pathway inhibition The invention is based upon the discovery that the EGFR pathway can stimulate a previously unknown tumorigenic function of CA IX, via phosphorylation of the sole tyrosine residue present in CA IX's intracellular domain. EGFR-phosphorylated CA IX then interacts with ... | 10/26/2010 |
| 7816496 | MN gene and protein A new gene—MN—and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenic... | 10/19/2010 |
| 7816493 | Soluble form of carbonic anhydrase IX (S-CA IX), assays to detect s-CA IX, CA IX'S coexpression with HER-2/NEU/C-ERBB-2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) found in body fluids, such as, urine and serum. Soluble CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a ... | 10/19/2010 |
| 7781470 | Aminodicarboxylic acid derivatives having pharmaceutical properties The invention relates to compounds of formulae (II), (IV), and (VI) as shown below, wherein the several variable groups are as defined in the specification and claims. Processes for making these materials, and methods for u... | 08/24/2010 |
| 7776922 | Substituted [(phenylethanoyl)amino]benzamides The invention relates to substituted [(phenylethanoyl)amino]benzamides and methods for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of inflammatory disorders such as, for example,... | 08/17/2010 |
| 7741048 | MN/CA IX and cancer prognosis Herein disclosed are methods that are prognostic for neoplastic/preneoplastic disease in a subject vertebrate, wherein said disease is associated with a tissue that normally expresses MN, but which MN expression is lost or diminished upon carcinogenesis. Exemplary o... | 06/22/2010 |
| 7713704 | MN gene and protein Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular co... | 05/11/2010 |
| 7550424 | CA IX-specific inhibitors Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably membrane-impermeant compounds, which inhibit the enzymati... | 06/23/2009 |
| 7524634 | MN/CA IX and cancer prognosis Herein disclosed are methods that are prognostic for neoplastic/preneoplastic disease in a subject vertebrate, wherein said disease is associated with a tissue that normally expresses MN, but which MN expression is lost or diminished upon carcinogenesis. Exemplary o... | 04/28/2009 |
| 7132395 | Antiviral methods using human rhinovirus receptor (ICAM-1) Method of inhibiting human rhinovirus (HRV) Infection by contacting said HRV with a polypeptide comprising a fragment of human rhinovirus major receptor (HRR), said fragment comprising the HRV binding site and being selected from a specific group consisting of HRR d... | 11/07/2006 |
| 4873196 | Protoplasts of temperature-sensitive strains of neurospora crassa OS-1 This invention concerns conditional protoplasts of temperature-sensitive variants of the osmotic-1 mutant strain of Neurospora crassa, and method of making same.... | 10/10/1989 |
| 4847207 | Process for detection of organosulfur compounds and apparatus therefor An organosulfur compound is detected and/or quantified, optionally in admixture with one or more other compounds, by reacting the organosulfur compound with gaseous fluorine at sub-atmospheric pressure and observing the chemiluminescence which develops. D... | 07/11/1989 |
| 4769331 | Recombinant methods and materials Specific DNA sequence insertions, deletions and substitutions (i.e., combinations of sequence deletion and insertion) in eukaryotic cell or viral genomes are stably effected through use of selectable DNA sequences comprising a herpesvirus thymidine kinase... | 09/06/1988 |
| 4663309 | Novel peptide hormones with calcitonin-like activity Compounds of the formula: ##STR1## wherein R1 is a moiety selected from the group consisting of ##STR2## R2 -R22 are amino acid moieties wherein R2 is an optional moiety which when present is selected ... | 05/05/1987 |
| 4656141 | High-performance liquid chromatography process and apparatus and composition of matter therefor A process for detecting the presence of trace amounts of non-fluorescent soluble compounds each having at least one labile hydrogen atom in a carrier solution by adding a non-fluorescent quinone which is reducible to a fluorescent hydroquinone, and irradi... | 04/07/1987 |
| 4601842 | Prevention of freezing at moderate supercooling using biogenic ice nucleation inhibitors A biogenic ice nucleation inhibitor, derivable from a source plant which is normally subjected to freezing stress in its natural habitat, is employed for protecting light frost-sensitive plants against frost injury by inhibiting the ice-nucleating activit... | 07/22/1986 |
| 4590159 | Enhancement of expression of protein synthesis in E. coli Endogenous and exogenous gene directed expression of protein synthesis in Escherichia coli is enhanced by transformation to incorporate a dominant mucoid mutant allele of the capR (lon) gene, preferably through use of the DNA plasmid, pBZ201M9 (A.T.C.C. P... | 05/20/1986 |
| 4570629 | Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same Hydrophilic biopolymeric copolyelectrolytes comprising (a) a water-soluble linear anionic protein polyelectrolyte component derived from keratin and (b) a water-soluble linear cationic biopolymer polyelectrolyte component derived from at least one biopoly... | 02/18/1986 |
| 4514331 | Peptide hormones with calcitonin-like activity Compounds of the formula: ##STR1## wherein R1 is a moiety selected from the group consisting of ##STR2## R2 -R22 are amino acid moieties wherein R2 is an optional moiety which when present is selected ... | 04/30/1985 |
| 4499075 | Antibiotic agents from S. coeruleorubidus, rubidus This invention relates to new polypeptide antibiotics designated LL-BO2964, LL-BO2964ଲ, LL-BO2964γ, and a mixture thereof designated LL-BO2964, produced during microbiological fermentation, under controlled conditions, using a new strain of ... | 02/12/1985 |
| 4484409 | Prevention of freezing at moderate supercooling using synthetic polymeric ice nucleation inhibitors A synthetic polymeric ice nucleation inhibitor is employed for protecting light frost-sensitive plants against frost injury by inhibiting the ice-nucleating activity of the ice-nucleating bacteria normally present on the plants, and thereby reducing the t... | 11/27/1984 |
| 4461833 | Chromatographically purifying proteolytic procoagulant enzyme from animal tissue extract A chromatographic procedure for the purification of a proteolytic procoagulant enzyme from extracts of human and animal tumors. The extracts are sequentially contacted with a first benzamide affinity chromatographic resin, an agarose filtration gel, a sec... | 07/24/1984 |
| 4393055 | Hydroxyalkyl ether derivatives of rutin poly(H-)sulfate and method of use Hydroxyalkyl ether derivatives of rutin poly(H-)sulfate and salts thereof useful as complement inhibitors.... | 07/12/1983 |
| 4342753 | Carboxyalkyl derivatives of rutin poly(H-)sulfate Carboxyalkyl derivatives of rutin polyl(H-)sulfate and salts thereof useful as complement inhibitors.... | 08/03/1982 |
| 4342752 | Carbalkoxymethyl derivatives of rutin poly(H-)sulfate and method of use Carbalkoxymethyl derivatives of rutin poly(H-)sulfate and salts thereof useful as complement inhibitors.... | 08/03/1982 |
| 4334058 | Rutin poly(H--)sulfate salts and related compounds Rutin poly(H--)sulfate and salts thereof useful as complement inhibitors.... | 06/08/1982 |
| 4334062 | Cephalosporanic acid derivatives 7-Acetamidocephalosporins are disclosed herein which are substituted at position 3 of the cephalosporin nucleus with the group ##STR1## wherein R2 is selected from the group hydrogen, amino, C1 to C6 alkylamino and di... | 06/08/1982 |
